TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

计划入组 30 人 · 首次发布于 2025 年 12 月 16 日

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

计划入组 76 人 · 首次发布于 2015 年 7 月 17 日

Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC

计划入组 30 人 · 首次发布于 2024 年 9 月 19 日

Bacillus Calmette Guerin Medac(Medac SrL)

Pegylated recombinant asparaginase(medac GmbH)

radiolabelled FAPI-46 (PDAC,/solid tumor/cancer),

Medac Gesellschaft für klinische Spezialpräparate m.b.H.

Germany

medac Gesellschaft für klinische Spezialpräparate mbH

Germany

NALIRIFOX Shows Numerically Improved Overall Survival Compared to FOLFIRINOX in Metastatic PDAC

Oleclumab Plus Chemotherapy Shows Promise in Metastatic Pancreatic Cancer

Phase 1 Trial Shows Promise for PSCA-Targeted BPX-601 CAR T-Cell Therapy in Pancreatic and Prostate Cancers